USSTOCK.TODAY
Market Closed
Log in Sign up

Johnson & Johnson Announces Positive Phase 1 Results for Prostate Cancer Treatment JNJ-6143

The Motley Fool +1 · ·by G4L

JNJ Johnson & Johnson
$267.14 -2.04%
View chart & analysis →
  1. 1Johnson & Johnson paid $3.05 billion to acquire Halda Therapeutics last year.
  2. 2JNJ-6143 recorded a 75% overall response rate among patients with measurable disease in the Phase 1 clinical trial.
  3. 3The Phase 1 results for JNJ-6143 are very encouraging, demonstrating the strength of Johnson & Johnson's pipeline.

So what's the key point?

Johnson & Johnson paid $3.05 billion as the acquisition price for Halda Therapeutics last year.

Source The Motley Fool +1 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →